Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO).

Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO).

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel ...

About this time a farmer buddy gave me some aronia berry juice and told me to drink it daily. I did. It’s high in antioxidants and anti-inflammatories. By the time we arrived at the U of I, the red ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Lung cancer is a big problem. It claims many lives each year. Around 160,000 people die annually in the US. This figure is ...

Inoviq has issued a lengthy response to the ASX's 'please explain' pertaining to the company's early-stage cancer work.

A new cancer treatment that delivers radiation directly to tumors by targeting two key markers simultaneously has been shown ...

Vlad Vitoc, M.D., is Chairman of Board, Chief Executive Officer, and President of MAIA Biotechnology Inc. Dr. Vitoc has a ...

Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why ...